144 related articles for article (PubMed ID: 16843075)
1. Acid-suppressive effects of rabeprazole: comparing 10mg and 20mg twice daily in Japanese Helicobacter pylori-negative and -positive CYP2C19 extensive metabolisers.
Shimatani T; Moriwaki M; Xu J; Tazuma S; Inoue M
Dig Liver Dis; 2006 Nov; 38(11):802-8. PubMed ID: 16843075
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamic studies on PPIs: look carefully at the country of origin.
Savarino V; Savarino E; Dulbecco P
Dig Liver Dis; 2006 Nov; 38(11):808-10. PubMed ID: 16945598
[No Abstract] [Full Text] [Related]
3. Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status.
Sugimoto M; Furuta T; Shirai N; Kajimura M; Hishida A; Sakurai M; Ohashi K; Ishizaki T
Clin Pharmacol Ther; 2004 Oct; 76(4):290-301. PubMed ID: 15470328
[TBL] [Abstract][Full Text] [Related]
4. Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19.
Shimatani T; Inoue M; Kuroiwa T; Xu J; Mieno H; Nakamura M; Tazuma S
Clin Pharmacol Ther; 2006 Jan; 79(1):144-52. PubMed ID: 16413249
[TBL] [Abstract][Full Text] [Related]
5. CYP2C19 genotype and the PPIs--focus on rabeprazole.
Lim PW; Goh KL; Wong BC
J Gastroenterol Hepatol; 2005 Dec; 20 Suppl():S22-8. PubMed ID: 16359346
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection in relation to CYP2C19 genotype.
Lee SB; Park SJ; Ryu JK; Lee JK; Kim HJ; Bae JS; Jung HS; Park SM
Korean J Gastroenterol; 2003 Dec; 42(6):468-75. PubMed ID: 14695703
[TBL] [Abstract][Full Text] [Related]
7. Rabeprazole 10 mg twice daily is superior to 20 mg once daily for night-time gastric acid suppression.
Shimatani T; Inoue M; Kuroiwa T; Horikawa Y
Aliment Pharmacol Ther; 2004 Jan; 19(1):113-22. PubMed ID: 14687173
[TBL] [Abstract][Full Text] [Related]
8. Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan.
Dojo M; Azuma T; Saito T; Ohtani M; Muramatsu A; Kuriyama M
Dig Liver Dis; 2001 Nov; 33(8):671-5. PubMed ID: 11785712
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism.
Hokari K; Sugiyama T; Kato M; Saito M; Miyagishima T; Kudo M; Nishikawa K; Ishizuka J; Komatsu Y; Mizushima T; Kagaya H; Hige S; Takeda H; Asaka M
Aliment Pharmacol Ther; 2001 Sep; 15(9):1479-84. PubMed ID: 11552922
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes.
Horai Y; Kimura M; Furuie H; Matsuguma K; Irie S; Koga Y; Nagahama T; Murakami M; Matsui T; Yao T; Urae A; Ishizaki T
Aliment Pharmacol Ther; 2001 Jun; 15(6):793-803. PubMed ID: 11380317
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: a 1-week, randomized, open-label study in Chinese adults.
Pan X; Li Y; Qiu Y; Tang Q; Qian B; Yao L; Shi R; Zhang G
Clin Ther; 2010 Nov; 32(12):2003-11. PubMed ID: 21118735
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic and kinetic effect of rabeprazole on serum gastrin level in relation to CYP2C19 polymorphism in Chinese Hans.
Hu YM; Mei Q; Xu XH; Hu XP; Hu NZ; Xu JM
World J Gastroenterol; 2006 Aug; 12(29):4750-3. PubMed ID: 16937451
[TBL] [Abstract][Full Text] [Related]
13. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.
Sahara S; Sugimoto M; Uotani T; Ichikawa H; Yamade M; Iwaizumi M; Yamada T; Osawa S; Sugimoto K; Umemura K; Miyajima H; Furuta T
Aliment Pharmacol Ther; 2013 Nov; 38(9):1129-37. PubMed ID: 24099474
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the effect on intragastric pH of a single dose of omeprazole or rabeprazole: which is suitable for on-demand therapy?
Inamori M; Togawa J; Takahashi K; Yoneda M; Fujisawa N; Iwasaki T; Ozawa Y; Kikuchi T; Muramatsu K; Chiguchi G; Matsumoto S; Kawamura H; Abe Y; Kirikoshi H; Kobayashi N; Sakaguchi T; Takamura T; Nakajima A; Ueno N; Sekihara H
J Gastroenterol Hepatol; 2003 Sep; 18(9):1034-8. PubMed ID: 12911659
[TBL] [Abstract][Full Text] [Related]
15. Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan.
Miki I; Aoyama N; Sakai T; Shirasaka D; Wambura CM; Maekawa S; Kuroda K; Tamura T; Kita T; Sakaeda T; Okumura K; Kasuga M
Eur J Gastroenterol Hepatol; 2003 Jan; 15(1):27-33. PubMed ID: 12544691
[TBL] [Abstract][Full Text] [Related]
16. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers.
Saitoh T; Fukushima Y; Otsuka H; Hirakawa J; Mori H; Asano T; Ishikawa T; Katsube T; Ogawa K; Ohkawa S
Aliment Pharmacol Ther; 2002 Oct; 16(10):1811-7. PubMed ID: 12269976
[TBL] [Abstract][Full Text] [Related]
17. [Effect of CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with rabeprazole-based triple therapy in Chinese].
He XX; Zhao YH; Hao YT
Zhonghua Nei Ke Za Zhi; 2004 Jan; 43(1):13-5. PubMed ID: 14990013
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotype in healthy Chinese subjects.
Hu YM; Xu JM; Mei Q; Xu XH; Xu SY
Acta Pharmacol Sin; 2005 Mar; 26(3):384-8. PubMed ID: 15715938
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of low-dose proton pump inhibitor (PPI) in the eradication of Helicobacter pylori following combination PPI/AC therapy in Japan.
Kawai T; Kawakami K; Mikinori K; Takei K; Itoi T; Moriyasu F; Takagi Y; Aoki T; Watanebe K; Matsumoto Y; Rimbara E; Noguchi N; Sasatsu M
Hepatogastroenterology; 2007 Mar; 54(74):649-54. PubMed ID: 17523342
[TBL] [Abstract][Full Text] [Related]
20. CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor.
Furuta T; Sugimoto M; Shirai N; Ishizaki T
Pharmacogenomics; 2007 Sep; 8(9):1199-210. PubMed ID: 17924835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]